Several studies havefocused on the development and applicationof radiolabeled DOTA-AE105 for targeting the urokinase-type plasminogenactivator receptor (uPAR), which is expressed on various cancer types.The aim of this project was to design and evaluate novel uPAR-targetingradiopeptides with improved pharmacokinetic properties in view oftheir therapeutic application. Here, PLAUR is linked to cancer.